Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thoracoscopic direct-view intrathoracic intercostal nerve block for postoperative pain after VATS
ChiCTR2300069138Phase 4Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ropivacaine in bronchial carcinoma (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Cumulative opioid dose (equivalent morphine dose) 24h postoperatively. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
ropivacaine
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2300069138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069138.